Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

$Virax Biolabs (VRAX.US)$ incoming dilution? LONDON, Aug. 21...

$Virax Biolabs (VRAX.US)$ incoming dilution?
LONDON, Aug. 21, 2024 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,108,892 of its ordinary shares at a purchase price of $4.50 per share in a registered direct offering. The closing of the offering is expected to occur on or about August 23, 2024, subject to the satisfaction of customary closing conditions.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
1
1
1
+0
4
Translate
Report
8310 Views
165Followers
19Following
1068Visitors
Follow